Related Experiment Video
Updated: Jun 3, 2026
06:07
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Overview of the oral HIV/AIDS Research Alliance Program
C H Shiboski1, J Y Webster-Cyriaque, M Ghannoum
1Department of Orofacial Sciences, School of Dentistry, University of California-San Francisco, San Francisco, California, USA. caroline.shiboski@ucsf.edu
Advances in Dental Research
|March 29, 2011
Summary
The Oral HIV/AIDS Research Alliance studies oral health complications in HIV/AIDS patients, focusing on how antiretrovirals affect lesions and pathogens. Oral fluids are also being investigated for HIV monitoring and diagnosis.
Area of Science:
- Oral health research
- HIV/AIDS clinical trials
- Infectious disease epidemiology
Background:
- The Oral HIV/AIDS Research Alliance operates within the global AIDS Clinical Trials Group.
- Research is funded by the National Institute of Dental and Craniofacial Research and the National Institute of Allergy and Infectious Diseases.
Purpose of the Study:
- Investigate evolving oral complications in HIV/AIDS.
- Assess the impact of antiretroviral therapies on oral mucosal lesions and associated infections.
- Explore the utility of oral fluids for monitoring HIV disease and coinfections.
Main Methods:
- Overview of the alliance's scientific agenda.
- Outline of ongoing and developing interventional and noninterventional clinical studies.
- Leveraging the infrastructure of the AIDS Clinical Trials Group in the US and internationally.
Main Results:
- The alliance focuses on the dynamic nature of HIV/AIDS and its oral manifestations.
- Key research areas include the effects of potent antiretrovirals on oral lesions.
- Exploration of fungal and viral pathogens in the context of HIV-associated oral conditions.
Conclusions:
- The Oral HIV/AIDS Research Alliance is advancing the understanding of oral health in the context of HIV/AIDS.
- Novel clinical studies aim to provide critical insights into disease management and diagnostics.
- Research contributes to improving patient outcomes through comprehensive oral health monitoring.
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:28International Nursing Organizations II
The World Health Organization (WHO) is a specialized agency of the United Nations based in Geneva. The WHO has many initiatives that center around health. Primarily, they lead global efforts to expand universal health coverage using science-based policies and programs. They are also responsible for shaping health research agendas and developing norms and standards.
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:26Sexually Transmitted Infections
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:03Dose-Response Relationship: Overview
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...